Tag : DiseaseModifying

Neurology

Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios

Newsemia
As available disease-modifying therapies (DMTs) increase, evaluating benefit/risk presents greater difficulties, requiring people with MS (PwMS) to play crucial roles in choosing treatment. Although individual...
Latest News

Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies

Newsemia
Frisoni, GB; Molinuevo, JL; Altomare, D; Carrera, E; Barkhof, F; Berkhof, J; Delrieu, J; … Ritchie, C; + view all Frisoni, GB; Molinuevo, JL; Altomare,...
Cardiology

Spironolactone: Diuretic or Disease-modifying Drug in Heart Failure with Preserved Ejection Fraction?

Newsemia
Related Articles Spironolactone: Diuretic or Disease-modifying Drug in Heart Failure with Preserved Ejection Fraction? Eur J Heart Fail. 2020 Aug 19;: Authors: Verbrugge FH, Damman...
Pharma / Biotech

A Small-Molecule Inhibitor of the Wnt Pathway, Lorecivivint (SM04690), as a Potential Disease-Modifying Agent for the Treatment of Degenerative Disc Disease.

Newsemia
A Small-Molecule Inhibitor of the Wnt Pathway, Lorecivivint (SM04690), as a Potential Disease-Modifying Agent for the Treatment of Degenerative Disc Disease. Spine J. 2020 May...
Neurology

Editors' note: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Newsemia
In the special article “Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis,” Rae-Grant et al. reported the findings of the Guideline Development, Dissemination,...
Neurology

Reader response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Newsemia
Genentech recognizes that high-quality and trustworthy guidelines, such as those published by the American Academy of Neurology, are important both for providers to optimize patient...
Neurology

Author response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Newsemia
I thank Dr. Tran for the comment on our comprehensive systematic review summary for the American Academy of Neurology guideline on disease-modifying therapy for adults...
Neurology

Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Newsemia
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of...
Neurology

Author response: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Newsemia
I thank Dr. Saltonstall for the comments and interest in this guideline.1 The development of a guideline covering 23 medications and 143 randomized trials, as...
Neurology

Editors' note: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Newsemia
In “Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy...
Neurology

Reader response: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Newsemia
Sanofi Genzyme applauds the American Academy of Neurology’s effort and leadership in releasing the evidence-based “Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple...
Neurology

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Newsemia
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World